<DOC>
	<DOCNO>NCT00143533</DOCNO>
	<brief_summary>The primary purpose study estimate maximum tolerate dose irinotecan use cefpodoxime pediatric solid tumor patient .</brief_summary>
	<brief_title>Prevention Diarrhea Patients Taking IV Irinotecan Relapsed Difficult Treat Pediatric Solid Tumors</brief_title>
	<detailed_description>This phase I study exploratory investigation least four dosage level ( 20 , 30 , 45 , 60 ) define tolerable dose phase II study . Primary consideration give determination qualitative quantitative toxicity administration irinotecan cefpodoxime , pharmacokinetics irinotecan give cefpodoxime . Standard phase I escalation study cohort 3-6 patient . Starting level 20 mg/m2/d , subsequent level 30 mg/m2/d , 45 mg/m2/d 60 mg/m2/d . An amendment study include intermediate level 40 mg/m2/d . Irinotecan administer 60-minute intravenous infusion daily 5 consecutive day , follow 2 day rest , follow additional 5 consecutive day course [ ( qd x 5 ) x 2 ] . Twenty-one day first dose consider one cycle therapy . Cefpodoxime give orally 10 mg/kg/day divide BID , start 2 day prior begin first course irinotecan , continue duration study participation . Additional objective include : - To describe pharmacokinetics intravenous irinotecan give oral cefpodoxime . - To describe dose-limiting toxicity/ies irinotecan give [ ( qd x 5 ) x 2 ] oral cefpodoxime . - To evaluate effect administration oral cefpodoxime amount intestinal beta-glucuronidase . - To correlate incidence severity diarrhea amount intestinal beta-glucuronidase . - To describe toxicity irinotecan give dos 20 mg/m2/d - To note tumor response within confines phase I trial</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cefpodoxime</mesh_term>
	<criteria>Subjects 21 year age time initial diagnosis Recurrent solid tumor show unresponsive conventional treatment disease , subject newly diagnose tumor conventional treatment available Histologic verification solid tumor malignancy original diagnosis Adequate performance status Neurologic deficits subject central nervous system ( CNS ) tumor must relatively stable minimum 2 week prior study entry Subjects must recover toxic effect prior chemotherapy enter study Adequate bone marrow , renal hepatic function No active infection time protocol entry , receive antibiotic P. carinii pneumonia prophylaxis . Patients must pregnant lactating . Patients must take enzymeinducing anticonvulsant ( e.g. , phenobarbital , phenytoin , carbamazepine ) , rifampin , St. John 's Wort . Dexamethasone use antiemetic . Patients must previous allergic reaction penicillin cephalosporin .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Solid Tumors</keyword>
</DOC>